

2B3, 11545 Rockville Pike, Rockville, Maryland.

The agenda for the subject meeting shall be as follows:

*Thursday, May 18, 2000—1 p.m. Until the Conclusion of Business*

The Subcommittee will: (1) Review the proposed final Regulatory Guide and Standard Review Plan Section supporting the revised Source Term Rule, and (2) discuss the status of the NRC and NEI program to address issues associated with control room habitability. The purpose of this meeting is to gather information, analyze relevant issues and facts, and to formulate proposed positions and actions, as appropriate, for deliberation by the full Committee.

Oral statements may be presented by members of the public with the concurrence of the Subcommittee Chairman. Written statements will be accepted and made available to the Committee. Electronic recordings will be permitted only during those portions of the meeting that are open to the public, and questions may be asked only by members of the Subcommittee, its consultants, and staff. Persons desiring to make oral statements should notify the cognizant ACRS staff engineer named below five days prior to the meeting, if possible, so that appropriate arrangements can be made.

During the initial portion of the meeting, the Subcommittee, along with any of its consultants who may be present, may exchange preliminary views regarding matters to be considered during the balance of the meeting.

The Subcommittee will then hear presentations by and hold discussions with representatives of the NRC staff, and other interested persons regarding this review.

Further information regarding topics to be discussed, whether the meeting has been canceled or rescheduled, the scheduling of sessions which are open to the public, and the Chairman's ruling on requests for the opportunity to present oral statements and the time allotted therefor, can be obtained by contacting the cognizant ACRS staff engineer, Mr. Paul A. Boehmert (telephone 301/415-8065) between 7:30 a.m. and 4:15 p.m. (EDT). Persons planning to attend this meeting are urged to contact the above named individual one or two working days prior to the meeting to be advised of any potential changes to the agenda, etc., that may have occurred.

Dated: May 2, 2000.

**Howard J. Larson,**

*Acting Associate Director for Technical Support, ACRS/ACNW.*

[FR Doc. 00-11388 Filed 5-5-00; 8:45 am]

**BILLING CODE 7590-01-P**

## **PRESIDIO TRUST**

### **Notice of Receipt of and Availability for Public Comment on an Application for Wireless Telecommunications Facilities Site; The Presidio of San Francisco, California**

**AGENCY:** The Presidio Trust.

**ACTION:** Public notice.

**SUMMARY:** This notice announces the Presidio Trust's receipt of and availability for public comment on an application from Bay Area Cellular Telephone Company, dba Cellular One, for a wireless telecommunications facilities site in The Presidio of San Francisco (the "Project"). The proposed location of the Project is in the parking area located directly below the Doyle Drive overpass in the vicinity of the intersection of Halleck and Vallejo Streets, San Francisco, California (the "Project Site").

The Project involves (i) placing a single utility pole and a one-story equipment building at the Project Site (alternatively, the equipment may be housed in an existing building, obviating the need for an equipment building), and (ii) removing five existing utility poles and lines, burying the lines underground. The utility pole will be approximately 50 feet tall. The one-story equipment building will be 9 feet by 15 feet. Power for the Project will be provided through underground coaxial cables connected to existing power sources. Connection to telephone lines will be through existing telephone lines.

**Comments:** Comments on the proposed Project must be sent to Devon Danz, Presidio Trust, 34 Graham Street, PO Box 29052, San Francisco, CA 94129-0052, and be received by June 7, 2000. A copy of Cellular One's application is available upon request to the Presidio Trust.

**FOR FURTHER INFORMATION CONTACT:** Devon Danz, Presidio Trust, 34 Graham Street, PO Box 29052, San Francisco, CA 94129-0052. Telephone: 415-561-5300.

Dated: May 2, 2000.

**Karen A. Cook,**

*General Counsel.*

[FR Doc. 00-11384 Filed 5-5-00; 8:45 am]

**BILLING CODE 4310-4R-P**

## **SECURITIES AND EXCHANGE COMMISSION**

### **Submission for OMB Review; Comment Request**

Upon Written Request, Copies Available From: Securities and Exchange Commission, Office of Filings and Information Services, 450 Fifth Street, N.W., Washington, D.C. 20549.

**Extension: Rule 30b2-1, SEC File No. 270-213, OMB Control No. 3235-0218.**

Notice is hereby given that, pursuant to the Paperwork Reduction Act of 1995 ("Act") [44 U.S.C. 3501 *et seq.*], the Securities and Exchange Commission ("Commission") has submitted to the Office of Management and Budget ("OMB") a request for extension of the previously approved collection of information discussed below.

### **Rule 30b2-1 Under the Investment Company Act of 1940, Filing of Copies of Reports to Stockholders**

Rule 30b2-1 under the Investment Company Act of 1940 [17 CFR 270.30b2-1] requires the filing of four copies of every periodic or interim report transmitted by or on behalf of any registered investment company to its stockholders.<sup>1</sup> This requirement ensures that the Commission has information in its files to perform its regulatory functions and to apprise investors of the operational and financial condition of registered investment companies.<sup>2</sup>

It is estimated that approximately 3,490 registered management investment companies are required to send reports to stockholders at least twice annually. The annual burden of filing the reports is estimated to be negligible.

The burden estimate for Rule 30b2-1 is made solely for the purposes of the Act and is not derived from a comprehensive or even representative survey or study of the costs of Commission rules and forms.

The collection of information under Rule 30b2-1 is mandatory. The information provided by Rule 30b2-1 is not kept confidential. The Commission may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.

<sup>1</sup> Most filings are made via the Commission's electronic filing system; therefore, paper filings under Rule 30b2-1 occur only in exceptional circumstances. Electronic filing eliminates the need for multiple copies of filings.

<sup>2</sup> Annual and periodic reports to the Commission become part of its public files and, therefore, are available for use by prospective investors and stockholders.

General comments regarding the above information should be directed to the following persons: (i) Desk Officer for the Securities and Exchange Commission, Office of Information and Regulatory Affairs, Office of Management and Budget, New Executive Office Building, Washington, D.C. 20503; and (ii) Michael E. Bartell, Associate Executive Director, Office of Information Technology, Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549. Comments must be submitted to OMB within 30 days of this notice.

Dated: May 1, 2000.

**Jonathan G. Katz,**  
*Secretary.*

[FR Doc. 00-11403 Filed 5-5-00; 8:45 am]

BILLING CODE 8010-01-M

## SECURITIES AND EXCHANGE COMMISSION

### Issuer Delisting; Notice of Application To Withdraw From Listing and Registration; (Maxim Pharmaceuticals, Inc., Common Stock, \$.001 Par Value, and Redeemable Common Stock Purchase Warrants Expiring July 10, 2001) File No. 1-14430

May 2, 2000.

Maxim Pharmaceuticals, Inc. ("Company") has filed an application with the Securities and Exchange Commission ("Commission"), pursuant to Section 12(d) of the Securities Exchange Act of 1934 ("Act")<sup>1</sup> and Rule 12d2-2(d) thereunder,<sup>2</sup> to withdraw the securities described above ("Securities") from listing and registration on the American Stock Exchange LLC ("Amex") and under Section 12(b) of the Act.<sup>3</sup>

The Company, whose business is biotechnology, has undertaken to transfer trading in its Securities from the Amex to the National Market of the Nasdaq Stock Market, Inc. ("Nasdaq"), which it considers to be the preeminent marketplace for the securities of biotechnology companies. The Company has registered its Securities pursuant to Section 12(g) of the Act<sup>4</sup> by filing a Registration Statement on Form 8-A with the Commission on April 26, 2000. The Securities subsequently became designated for quotation and began trading on the Nasdaq National Market, and were simultaneously suspended from trading on the Amex, on April 27, 2000. In making the

determination to withdraw its Securities from listing and registration on the Amex in conjunction with the commencement of trading on the Nasdaq, the Company hopes to avoid both the costs of maintaining dual listings and potential fragmentation of the market for its Securities.

The Company has stated that it has complied with the Rules of the Amex governing the withdrawal of its Securities from listing and registration on the Exchange, and that the Amex in turn has indicated that it will not oppose such withdrawal.

The Company's application relates solely to the withdrawal of the Securities from listing and registration on the Amex and shall have no effect upon the Securities' designation for quotation and trading on the Nasdaq National Market and registration under Section 12(g) of the Act.<sup>5</sup>

Any interested person may, on or before May 23, 2000, submit by letter to the Secretary of the Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549-0609, facts bearing upon whether the application has been made in accordance with the rules of the Amex and what terms, if any, should be imposed by the Commission for the protection of investors. The Commission, based on the information submitted to it, will issue an order granting the application after the date mentioned above, unless the Commission determines to order a hearing on the matter.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority.<sup>6</sup>

**Jonathan G. Katz,**  
*Secretary.*

[FR Doc. 00-11401 Filed 5-5-00; 8:45 am]

BILLING CODE 8010-01-M

## SECURITIES AND EXCHANGE COMMISSION

### Issuer Delisting; Notice of Application To Withdraw From Listing and Registrations; (Rogers Corporation, Capital Stock, \$1 Par Value, and Rights to Purchase Capital Stock, \$1 Par Value) File No. 1-04347

May 2, 2000.

Rogers Corporation ("Company") has filed an application with the Securities and Exchange Commission ("Commission"), pursuant to Section 12(d) of the Securities Exchange Act of

1934 ("Act")<sup>1</sup> and Rule 12d2-2(d) thereunder,<sup>2</sup> to withdraw the securities to described above ("Securities") from listing and registration on the American Stock Exchange LLC ("Amex").

The Company is seeking to withdraw its Securities from listing and registration on the Amex in conjunction with the commencement of their trading on the New York Stock Exchange, Inc. ("NYSE"). The Company hopes that, with a NYSE listing, it will be able to realize a broader market base for its Securities than it has had through the Amex.

Subsequent to the filing of the Company's Registration Statements on Form 8-A with the Commission, which became effective on April 6, 2000, trading in the Securities commenced on the NYSE, and was simultaneously suspended on the Amex, at the opening of business on April 18, 2000. In making the determination to withdraw its Securities from listing and registration on the Amex in conjunction with the new listing and registration on the NYSE, the Company hopes to avoid both the costs associated with maintaining dual listings and potential fragmentation of the market for its Securities.

The Company has stated that it has complied with the rules of Amex governing the withdrawal of its Securities, and the Amex in turn has indicated that it will not oppose such withdrawal.

The Company's application relates solely to the withdrawal of the Securities from listing and registration on the Amex and shall have no effect upon the Securities' continued listing and registration on the NYSE. By reason of Section 12(b) of the Act<sup>3</sup> and the rules and regulations of the Commission thereunder, the Company shall continue to be obligated to file reports with the Commission under Section 13 of the Act.<sup>4</sup>

Any interested person may, on or before May 23, 2000, submit by letter to the Secretary of the Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549-0609, facts bearing upon whether the application has been made in accordance with the rules of the Amex and what terms, if any, should be imposed by the Commission for the protection of investors. The Commission, based on the information submitted to it, will issue an order granting the application after the date

<sup>1</sup> 15 U.S.C. 78l(d).

<sup>2</sup> 17 CFR 240.12d2-2(d).

<sup>3</sup> 15 U.S.C. 78l(b).

<sup>4</sup> 15 U.S.C. 78l(g).

<sup>5</sup> *Id.*

<sup>6</sup> 17 CFR 200.30-3(a)(1).

<sup>1</sup> 15 U.S.C. 78l(d).

<sup>2</sup> 17 CFR 240.12d2-2(d).

<sup>3</sup> 15 U.S.C. 78l(b).

<sup>4</sup> 15 U.S.C. 78m.